JCM Accepted Manuscript Posted Online 15 April 2020
J. Clin. Microbiol. doi:10.1128/JCM.00721-20
Copyright © 2020 Péré et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

l

D
o
w
n
o
a
d
e
d
 
f
r
o
m
 
h
t
t
p
:
/
/
j
c
m
.
a
s
m
.
o
r
g
/
 
o
n
 
A
p
r
i
l
 
1
8
,
 
2
0
2
0
 
b
y
 
g
u
e
s
t

1  Nasal swab sampling for SARS-CoV-2:  1 A convenient alternative in time of nasopharyngeal swab shortage 2  3 Hélène Péré1,2,3, Isabelle Podglajen3,4, Maxime Wack5,6, Edouard Flamarion7, 4 Tristan Mirault2,8, Guillaume Goudot2,8, Caroline Hauw-Berlemont9, Laetitia Le10,11, 5 Eric Caudron10,11, Sophie Carrabin7, Julien Rodary1, Tatiana Ribeyre1, 6 Laurent Bélec1,3,4, David Veyer1,3,12,# 7  8  9 1Laboratoire de Virologie, Hôpital Européen Georges Pompidou,  10 Assistance Publique-Hôpitaux de Paris, Paris, France ; 11 2INSERM U970, PARCC, Hôpital Européen Georges Pompidou,  12 Faculté de Médecine, Université de Paris, Paris, France ; 13 3Service de Microbiologie, Hôpital Européen Georges Pompidou,  14 Assistance Publique-Hôpitaux de Paris, Paris, France ; 15 4Faculté de Médecine Paris Descartes, Sorbonne Paris Cité, Université de Paris, Paris, France ; 16 5Département d’Informatique Médicale, Biostatistiques et Santé Publique,  17 Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris, Paris, France ; 18 6Centre de Recherche des Cordeliers, INSERM, UMRS 1138, Université de Paris, Paris, France ; 19 7Département de Médecine Interne, Hôpital Européen Georges Pompidou,  20 Assistance Publique-Hôpitaux de Paris, Paris, France ; 21 8Départment de Médecine Vasculaire, HYPERVASC, Hôpital Européen Georges Pompidou, 22 Assistance Publique-Hôpitaux de Paris, Paris, France ; 23 9Service de Médecine Intensive-Réanimation, Hôpital Européen Georges Pompidou,  24 Assistance Publique-Hôpitaux de Paris, Paris, France ; 25 10Laboratoire de Chimie Analytique Pharmaceutique, EA7357,  26 Université Paris Sud- Paris-Saclay, Châtenay-Malabry, France ; 27 11Départment de Pharmacie, Hôpital Européen Georges Pompidou,  28 Assistance Publique-Hôpitaux de Paris, Paris, France ; 29 12Unité de Génomique Fonctionnelle des Tumeurs Solides, Centre de Recherche des Cordeliers, 30 INSERM, Université de Paris, Paris, France. 31  32  33  34 Running title: Nasal swab for SARS-CoV-2 molecular detection 35  36  37  38  39  40  41  42  43  44  45  46  47  48 #Corresponding author: Dr David Veyer, Pharm D, PhD, Laboratoire de virologie, Hôpital 49 Européen Georges Pompidou, 20 Rue Leblanc 75015 Paris France, Tel: (33)1 56 09 39 59; 50 fax: (33)1 56 09 24 47; electronic address: david.veyer@aphp.fr  51 l

D
o
w
n
o
a
d
e
d
 
f
r
o
m
 
h
t
t
p
:
/
/
j
c
m
.
a
s
m
.
o
r
g
/
 
o
n
 
A
p
r
i
l
 
1
8
,
 
2
0
2
0
 
b
y
 
g
u
e
s
t

2  Nasopharyngeal swab is the reference sampling method to detect SARS CoV2, as 52 recommended by world Health Organization (WHO) (1). However, the collection of nasal 53 specimens may have a slightly lower sensitivity than nasopharyngeal specimens (2, 3). We 54 herein validated an alternative procedure to collect nasal secretions with swab routinely used 55 in medical bacteriology for which there is no risk of supply disruption, in order to perform the 56 molecular diagnosis of SARS-CoV-2 infection. 57 Patients who were suspected of COVID-19 attending the Hôpital Européen Georges 58 Pompidou, Paris, France, were for their own care according to medical decision prospectively 59 included and subjected to SARS-CoV-2 molecular testing using nasopharyngeal swab [Xpert® 60 Nasopharyngeal Sample Collection Kit, Cepheid, Sunnyvale, CA, USA] and nasal swab 61 (Copan Transystem®, Copan, Brescia, Italy).  62 Nasal and nasopharyngeal swabs were inserted in the nostril until they hit an obstacle 63 (the inferior concha and the back of the nasopharyngeal cavity, respectively), rotated 5 times 64 and removed. The test was conducted in only one nostril per patient. After sampling, 65 nasopharyngeal swab was inserted into a vial containing 3 mL of virus transport medium 66 (Xpert® Viral Transport medium, Cepheid), and nasal swab was placed in a 15 mL tube 67 containing 3 mL of saline solution (NaCl 0.9%). SARS CoV-2 was detected using Allplex™ 68 2019-nCoV Assay (Seegene, Seoul, Korea). 69  A total of 44 patients were prospectively included up to the end of March 2020. Their 70 median age was 63.0 years, ranging from 18 to 94 years. There were 23 (52.3%) male and 21 71 female patients. A total of 37 (84.1%) patients showed laboratory-confirmed SARS-CoV-2 72 infection using nasopharyngeal swab, 7 remaining negative (15.9%) (Table 1). 73  Out of 37 patients that were positive for SARS-CoV-2 by nasopharyngeal swab 74 testing, 33 were also tested positive with nasal sampling. All SARS-CoV-2-negative patients 75 with nasopharyngeal swabs (n=7) tested negative using nasal swabs (Table 1). 76 l

D
o
w
n
o
a
d
e
d
 
f
r
o
m
 
h
t
t
p
:
/
/
j
c
m
.
a
s
m
.
o
r
g
/
 
o
n
 
A
p
r
i
l
 
1
8
,
 
2
0
2
0
 
b
y
 
g
u
e
s
t

3    By reference to nasopharyngeal sampling, the detection of SARS-CoV-2 by nasal 77 sampling provided 7 (15.9%) true SARS-CoV-2-negative specimens, 4 (9.1%) false negative 78 specimens and 33 (75.0%) true SARS-CoV-2-positive specimens. Thus, the sensitivity of 79 SARS-CoV-2 RNA detection by multiplex real-time PCR from nasal secretions was 89.2% 80 [95% confidence interval (CI); 75.3-95.7] and its specificity was 100.0% (95% CI; 94.6–81 100.0). The  index was 0.72, indicating substantial concordance between nasal and 82 nasopharyngeal swabbing to detect SARS-CoV-2 according the Landlis and Koch’s rank. The 83 Youden’s J index was calculated at 89.2%, demonstrating good efficiency to detect SARS-84 CoV-2 RNA. 85 Ct (mean±SD) values for E, RdRP, and N genes by nasopharyngeal (E: 23.9±4.9; 86 RdRP: 26.3±5.5; N: 28.9±6.1) and nasal (E: 22.3±5.2; RdRP: 24.6±5.9; N: 27.9±6.1) swabs 87 testing were of similar levels. Differences in Ct values for the E, RdRP, and N genes were not 88 statistically significant (p = 0.56, 0.84, and 0.57 respectively). 89 We herein report that the molecular detection of SARS-CoV-2 using nasal swab 90 specimens was nearly equivalent to the detection using nasopharyngeal swab considered as 91 the gold standard. SARS-CoV-2 detection from nasal samples showed high sensitivity and 92 specificity. Agreement and accuracy of test results using nasal sampling by reference to gold 93 standard nasopharyngeal sampling were estimated as substantial and good, respectively. 94 Taken together, these observations demonstrate that nasal sampling could be used to screen 95 SARS-CoV-2 in times of nasopharyngeal swab shortage. 96  97   98 l

D
o
w
n
o
a
d
e
d
 
f
r
o
m
 
h
t
t
p
:
/
/
j
c
m
.
a
s
m
.
o
r
g
/
 
o
n
 
A
p
r
i
l
 
1
8
,
 
2
0
2
0
 
b
y
 
g
u
e
s
t

4  Acknowledgments. We thank the patients, the nurses and clinical staff who are providing 99 care for the patients. 100 Conflicts of interest: None.  101  102 Funding statement: None. 103  104  105   106 l

D
o
w
n
o
a
d
e
d
 
f
r
o
m
 
h
t
t
p
:
/
/
j
c
m
.
a
s
m
.
o
r
g
/
 
o
n
 
A
p
r
i
l
 
1
8
,
 
2
0
2
0
 
b
y
 
g
u
e
s
t

5  References  107  108 1. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-109 nCoV) in suspected human cases. Interim guidance. 19 March 2020.  WHO/COVID-110 19/laboratory/2020.5. Available at: https://www.who.int/publications-111 detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-112 20200117 [Accessed 27 March 2020]. 113 2. Lambert, S.B., Whiley, D.M., O'Neill, N.T., Andrews, E.C., Canavan, F.M., Bletchly, 114 C, Siebert DJ, Sloots TP, Nissen MD. Comparing nose-throat swabs and 115 nasopharyngeal aspirates collected from children with symptoms for respiratory virus 116 identification using real-time polymerase chain reaction. Pediatrics. 2008; 122: e615–117 e620. 118 3. Meerhoff, T.J., Houben, M.L., Coenjaerts, F.E., Kimpen, J.L., Hofland, R.W., 119 Schellevis, F, Bont LJ.  Detection of multiple respiratory pathogens during primary 120 respiratory infection: nasal swab versus nasopharyngeal aspirate using real-time 121 polymerase chain reaction. Eur J Clin Microbiol Infect Dis. 2010; 29: 365-371. 122  123  124   125 l

D
o
w
n
o
a
d
e
d
 
f
r
o
m
 
h
t
t
p
:
/
/
j
c
m
.
a
s
m
.
o
r
g
/
 
o
n
 
A
p
r
i
l
 
1
8
,
 
2
0
2
0
 
b
y
 
g
u
e
s
t

6   126 Table 1. Comparison of nasopharyngeal versus nasal sampling for 127 SARS-CoV-2 detection by molecular biology. 128  129  Nasopharyngeal sample/Nasal sample results n (%)     Concordant results                         Positive/Positive 33 (75.0%)                       Negative/Negative 7 (15.9%)      Discordant results                        Positive/Negative* 4 (9.1%)      Total 44 (100.0%)   * Out of the 4 discordant results, 2 had very low viral loads (Ct=38 on the N gene). 130  131  132  133  134  135  136  137  138  139  140  141  142  143  144 